SCHEMBL6955824

SCHEMBL6955824

COc1cccc2oc(C(C)O)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
NQO2 P16083 5/20 0.40
F2RL3 Q96RI0 2/20 0.39
MCHR1 Q99705 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP2A6 P11509 1/20 0.37
EDNRA P25101 1/20 0.37
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
G6PD P11413 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22439323 0.87 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL20818979 0.81 EDNRA (0.43) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL20931268 0.76 F2RL3 (0.41) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL20931281 0.75 ELANE (0.49) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL9768577 0.75 NQO2 (0.46) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL20836961 0.74 F2RL3 (0.39) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL5036483 0.73 MCHR1 (0.50) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL30698496 0.73 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL10012992 0.73 NQO2 (0.44) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL27037459 0.73 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0944616-B1 BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE DARWIN DISCOVERY LTD (GB) 2003-06-04 EP disclosed
US-20020094987-A1 Bicyclic aryl carboxamides and their therapeutic use DYKE HAZEL JOAN (GB) 2002-07-18 US disclosed
US-6353010-B1 ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS DARWIN DISCOVERY, LTD. (GB) 2002-03-05 US disclosed
EP-0944616-A1 BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE Darwin Discovery Limited (GB) 1999-09-29 EP disclosed
WO-1998022460-A1 BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE DARWIN DISCOVERY LIMITED (GB) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094987-A1 Bicyclic aryl carboxamides and their therapeutic use PDE3B, PDE3A, PDE2A ALDH1A1 202/4885KDM4E 2000/4885HPGD 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.